Biggest News Aggregation in the World
📰 Looking Statement News

Page 41 - Looking Statement News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Looking Statement. Real-time updates on events, politics, business and more.

FDA Approves Merck's KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients ... | April 3, 2023
United States Seagen Padcev Eliav Barr Approval Program Drug Administration Patient Support Program

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors

KEYTRUDA is approved for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors, as determined by an FDA-approved test, that have progressed... | March 29, 2023
United States Luisa Diaz Jr Scot Ebbinghaus Merck Co Inc Merck Patient Support Program Memorial Sloan Kettering Cancer Center

Fosun Pharma Announces 2022 Annual Results: Achieved Steady Growth with Revenue from Record High Innovative Products and Global Commercialization Capability Improvement

Performance Highlights: During the reporting period, the revenue was RMB 43.952 billion, with a year-on-year growth of 12.66%; the net profit after deducting extraordinary gain or loss attributable... | March 28, 2023
United States Macau General Hong Kong Fosun Pharma Artesun Han Li Kang Rituximab Getz Pharma

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status

KEYTRUDA plus chemotherapy reduced risk of disease progression or death by 46% in patients whose cancer was mismatch repair proficient and by 70% in patients whose cancer was mismatch repair... | March 27, 2023
United States Merck Co Inc Statement Of Merck Co Inc Exchange Commission Society Of Gynecologic Oncology Gynecologic Oncology

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science